LIFECORE BIOMEDICAL, INC. Restructuring Costs and Asset Impairment Charges
LIFECORE BIOMEDICAL, INC. (LFCR) reported Restructuring Costs and Asset Impairment Charges of $1.40 million for the 12-month period ending 2024-05-26, per its 10-K filed 2024-08-26.
Discontinued › Cash Flow › Operating Activities
us-gaap:RestructuringCostsAndAssetImpairmentCharges · last filed 2024-08-26
- LIFECORE BIOMEDICAL, INC. restructuring costs and asset impairment charges for the quarter ending 2023-05-28 was $640.00K.
- LIFECORE BIOMEDICAL, INC. restructuring costs and asset impairment charges for the quarter ending 2023-02-26 was $0.00, a 100.00% decline year-over-year.
- LIFECORE BIOMEDICAL, INC. restructuring costs and asset impairment charges for the quarter ending 2022-11-27 was $0.00.
- LIFECORE BIOMEDICAL, INC. restructuring costs and asset impairment charges for the quarter ending 2022-08-28 was $0.00.
- LIFECORE BIOMEDICAL, INC. restructuring costs and asset impairment charges for fiscal 2024 was $1.40M, a 119.06% increase from fiscal 2023.
- LIFECORE BIOMEDICAL, INC. restructuring costs and asset impairment charges for fiscal 2023 was $640.00K.
- LIFECORE BIOMEDICAL, INC. restructuring costs and asset impairment charges for fiscal 2022 was $0.00.
- LIFECORE BIOMEDICAL, INC. restructuring costs and asset impairment charges for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
| Period end | Restructuring Costs and Asset Impairment Charges 3 month | Restructuring Costs and Asset Impairment Charges 6 month | Restructuring Costs and Asset Impairment Charges 9 month | Restructuring Costs and Asset Impairment Charges 12 month | Restructuring Costs and Asset Impairment Charges 12 month as first filed |
|---|---|---|---|---|---|
| 2024-05-26 | $1.40M 10-K · filed 2024-08-26 | ||||
| 2023-05-28 | $640.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-08-26 | $640.00K derived: sum of 2 quarters · filed 2024-08-26 | $640.00K derived: sum of 3 quarters · filed 2024-08-26 | $640.00K 10-K · filed 2024-08-26 | |
| 2023-02-26 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-06-02 | $0.00 derived: sum of 2 quarters · filed 2023-06-02 | $0.00 10-Q · filed 2023-06-02 | -$5.18M derived: sum of 4 quarters · filed 2024-08-26 | |
| 2022-11-27 | $0.00 derived: 10-Q 6 month − 10-Q/A 3 month · filed 2023-03-16 | $0.00 10-Q · filed 2023-03-16 | -$5.18M derived: sum of 3 quarters · filed 2024-08-26 | $92.00K derived: sum of 4 quarters · filed 2024-08-26 | |
| 2022-08-28 | $0.00 10-Q/A · filed 2023-03-16 | -$5.18M derived: sum of 2 quarters · filed 2024-08-26 | $92.00K derived: sum of 3 quarters · filed 2024-08-26 | $92.00K derived: sum of 4 quarters · filed 2024-08-26 | |
| 2022-05-29 | -$5.18M derived: 10-K 12 month − 10-Q 9 month · filed 2024-08-26 | $92.00K derived: sum of 2 quarters · filed 2024-08-26 | $92.00K derived: sum of 3 quarters · filed 2024-08-26 | $0.00 10-K · filed 2024-08-26 | $5.18M 10-K · filed 2022-09-14 |
| 2022-02-27 | $5.28M derived: 10-Q 9 month − 10-K 6 month · filed 2023-06-02 | $5.28M derived: sum of 2 quarters · filed 2024-03-20 | $5.18M 10-Q · filed 2023-06-02 | -$2.70M derived: sum of 4 quarters · filed 2024-03-20 | |
| 2021-11-28 | $0.00 derived: 10-K 6 month − 10-K 3 month · filed 2024-03-20 | -$92.00K 10-K · filed 2024-03-20 | -$7.97M derived: sum of 3 quarters · filed 2024-03-20 | -$6.10M derived: sum of 4 quarters · filed 2024-03-20 | |
| 2021-08-29 | -$92.00K 10-K · filed 2024-03-20 | -$7.97M derived: sum of 2 quarters · filed 2024-03-20 | -$6.10M derived: sum of 3 quarters · filed 2024-03-20 | -$6.10M derived: sum of 4 quarters · filed 2024-03-20 | |
| 2021-05-30 | -$7.88M derived: 10-K 12 month − 10-K 9 month · filed 2024-03-20 | -$6.00M derived: sum of 2 quarters · filed 2024-03-20 | -$6.00M derived: sum of 3 quarters · filed 2024-03-20 | $0.00 10-K · filed 2024-03-20 | $10.14M 10-K · filed 2021-07-29 |
| 2021-02-28 | $1.88M derived: 10-K 9 month − 10-Q 6 month · filed 2024-03-20 | $1.88M derived: sum of 2 quarters · filed 2024-03-20 | $7.88M 10-K · filed 2024-03-20 | ||
| 2020-11-29 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-01-07 | $6.00M 10-Q · filed 2022-01-07 | |||
| 2020-08-30 | $6.00M 10-Q · filed 2021-10-05 | ||||
| 2020-05-31 | $14.80M 10-K/A · filed 2023-03-16 | ||||
| 2019-05-26 | $0.00 10-K · filed 2021-07-29 | ||||
| 2018-05-27 | $0.00 10-K · filed 2020-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |